There’s been a shift in the acceptance of real-world data (RWD) and real-world evidence (RWE) in regulatory decision-making. What was once considered merely anecdotal is now deemed reliable. Between the FDA’s final 2017 guidance, the RWE Framework document from 2018, and the April 2021 report on RWE-based decisions, the agency is showing its increasing emphasis on real-world information.

The FDA’s Center for Devices and Radiological Health (CDRH) is moving with this trend, but it’s unclear whether FDA policies have actually evolved.

FDA regulatory expert Kristin Zielinski Duggan will dig into the FDA’s guidance around RWE as support for regulatory decision-making and detail key examples of how this evidence has been used for medical device decisions. She will discuss the limitations of these approaches and the steps you can take.

Key webinar takeaways:
FDA Guidance and Documentation
Understanding the FDA’s guidance document on the use of real-world evidence to support regulatory decision-making for medical devices
Analyzing the FDA’s framework for the RWE program
Exploring illustrative examples from the FDA’s April 2021 report on examples of RWE used in medical device regulatory decisions

Practicalities of Relying on RWD/RWE
The limitations of turning to RWD and RWE
Steps to successfully use RWD and RWE

Pre-market and Post-market Obligations
Using RWD and RWE for pre-market and post-market obligations

The FDA is shifting its acceptance of real-world data and evidence. If you’re planning on relying on RWD and RWE, you’ll need to understand these changes. Stay ahead of the curve and determine the best path forward.

Click here for additional information and registration details.

Related Content

Evidence Matters 2022

Evidence Matters 2022

Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.